In a nutshell This study evaluated the effectiveness of fulvestrant (Faslodex) plus capivasertib (AZD5363) in patients with aromatase inhibitor-resistant estrogen receptor-positive (ER+) and HER2-negative (HER2-) advanced breast cancer (BC). The data showed that fulvestrant plus capivasertib significantly improved the survival outcomes in these...
Read MoreType(s) of hormonal therapy-Aromatase inhibitors Posts on Medivizor
Extending therapy with aromatase inhibitors to 10 years in postmenopausal patients with hormone receptor-positive early-stage breast cancer.
In a nutshell This study evaluated the effectiveness and safety outcomes of extending treatment with letrozole (Femara), an aromatase inhibitor, to 10 years in postmenopausal patients with hormone receptor-positive (HR+) early-stage breast cancer (BC). The data showed that extending treatment with letrozole to 10 years significantly improved the...
Read MoreEvaluating the effectiveness of antiresorptive drugs on bone mineral density in postmenopausal women with early-stage breast cancer receiving treatment with aromatase inhibitors.
In a nutshell This study evaluated the effectiveness of antiresorptive drugs on bone mineral density (BMD) in postmenopausal women with early-stage breast cancer (BC) receiving treatment with aromatase inhibitors (AIs). The data showed that denosumab (Prolia) and zoledronic acid (Aclasta) were the most effective antiresorptive treatment options to...
Read MoreLooking for postmenopausal women with advanced breast cancer to try a hormonal therapy
In a nutshell This study is looking for postmenopausal patients with advanced breast cancer with an ESR1 mutation to compare lasofoxifene (Fablyn) to fulvestrant (Faslodex). The main outcome measured in this trial will be the patient’s survival without tumor growth or spread. This trial is recruiting in multiple locations in the United...
Read MoreJoint pain and falls among women with breast cancer on aromatase inhibitors.
In a nutshell This study wanted to find out if joint pain is associated with falling down in patients with breast cancer who were treated with aromatase inhibitors. The study found that the patients who reported having joint pain were more likely to have a fall than those who had no joint pain. Some background Aromatase inhibitors are medications...
Read MoreSearching for patients with advanced breast cancer to trial a new medication
In a nutshell This trial is aiming to determine how effective a new medication called elacestrant is for treating advanced breast cancer. The main outcome that will be measured is how long the patients go without the disease progressing. This study is being conducted in Illinois, United States. The details Some breast cancers grow in response to the...
Read MoreJoint pain management in obese breast cancer patients treated with aromatase inhibitors
In a nutshell This article investigated the safety and effectiveness of adding Omega-3 fatty acid (O3-FA) to the management of joint pain in patients with breast cancer treated with aromatase inhibitors. The authors concluded that the addition of O3-FA is safe and gave the greatest benefit to patients who were obese. Some background...
Read MoreA treatment option for advanced breast cancer patients with visceral metastasis
In a nutshell This study aimed to investigate the benefits of fulvestrant (Faslodex) treatment in advanced breast cancer patients. This study concluded that fulvestrant provides a benefit in patients with advanced breast cancer who have visceral metastasis. Some background Advanced breast cancer (ABC) has spread to the lymph nodes and...
Read MoreEverolimus plus exemestane – an effective combination therapy or not?
In a nutshell This study examined the addition of everolimus (Afinitor) to exemestane (Aromasin) for the treatment of patients with hormone-receptor-positive (HR+) and HER2- breast cancer. The study concluded that adding everolimus (EVE) to exemestane (EXE) did not significantly improve overall survival. Some background EXE is a treatment...
Read MoreCan anti-cancer medication increase the risk of bone fracture?
In a nutshell The authors aimed to evaluate the risk of fractures and overall bone health following treatment with aromatase inhibitors. Some background Aromatase inhibitors (AIs) are a class of drug used to treat estrogen receptor positive breast cancer (ER+; breast cancer that is dependent on the hormone estrogen for growth). Their use, however,...
Read MoreCould acupuncture help with the symptoms related to hormone therapy in breast cancer?
In a nutshell The authors aimed to determine if acupuncture could reduce medication-induced hot flashes in patients with breast cancer. Some background Aromatase inhibitors are a form of hormone therapy used for women with hormone-receptor positive breast cancer (dependent on the hormones estrogen or progesterone for growth). Hot flashes are an...
Read MoreHormone therapy; enabling surgery in post-menopausal breast cancer patients
In a nutshell The authors aimed to determine the long-term effects of hormone therapy to treat post-menopausal women with advanced breast cancer. Some background Hormone therapy is a form of breast cancer treatment. It targets cancer cells that may be affected by hormones. It is often administered prior to surgery in patients who are unfit to...
Read More